Inhibiting NKG2A/HLA-E interaction with a NKG2A blocking antibody significantly improved the ability of patient-derived NT NK cells, patient derived CD19-CAR NK cells, and CB CD19-CAR NK cells to kill primary CLL cells, however CB CD19-CAR NK cells consistently outperformed all other NK cell treatments with or without NKG2A blockade [149]. Here, KLRC1 is linked to B-cell chronic lymphocytic leukemia.